Roche gets priority review for melanoma drug cobimetinib
The US Food and Drug Administration has granted a priority review for Roche’s cobimetinib in combination with the company’s already-marketed melanoma drug Zelboraf.
Read MoreAuthor: Kevin Grogan
WHO urges govts to stump up $34 billion for NTDs
The World Health Organisation has urged affected countries to scale up their investment in tackling 17 neglected tropical diseases to improve the lives of more than 1.5 billion people.
Read MoreActavis changes name to Allergan as branded ops soar
Actavis says it will change its name to Allergan after the completion of its $66 billion acquisition of the Botox manufacturer.
Read MoreFDA expands approval on Celgene myeloma drug Revlimid
Celgene has been boosted by the news that the US Food and Drug Administration has expanded approval on its multiple myeloma blockbuster Revlimid to include newly-diagnosed patients.
Read MoreFerring buys BioSET’s orthobiologics
Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair.
Read More
